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Abstract
Background: Families of children affected with atopic dermatitis (AD) often report fear and anxiety regarding
treatment with topical corticosteroids (TCS), which may lead to reduced compliance. The objective of our study was
to measure, through a standardized questionnaire, fear of TCS in families of pediatric patients with AD and to
identify items associated with fear.
Methods: Families of pediatric patients with AD were enrolled in 9 Italian centers of pediatric dermatology.
Enrolled parents were invited to fill in a questionnaire including questions on sociodemographic and clinical
characteristics and 3 sets of questions on corticosteroid phobia (general fear, specific fears, behaviours regarding
TCS). Determinants of the level of general fear were investigated through multivariable analysis.
Results: A total of 300 outpatients with AD were enrolled. Most parents (80%) had a high instruction level. Eighty-one
percent reported to have a certain amount of fear of TCS. At the multivariable analysis, fear of TCS was associated with
the following items: believing that TCS treatment advantages do not overweight disadvantages (P = 0.011); believing
that TCS may be dangerous independently from the specific side effect (P < 0.001). Moreover, TCS fear was associated
with fear of applying too much cream (P = 0.001).
Conclusion: TCS phobia is widespread among Italian families of children with AD. Fear of TCS is associated with fear of
applying too much cream, thus increasing the risk of poor compliance and treatment failure. Therapeutic education of
families on the use of TCS should be implemented.
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Background
Atopic dermatitis (AD) is a common chronic, pruritic, in-
flammatory skin disease, mostly affecting children, with
heterogeneous lifetime prevalence figures, ranging world-
wide from 8 to 18% [1]. Although its exact pathogenesis
still remains unclear, it is well established that AD depends
on a combination of genetic and environmental factors. In
patients with AD, a genetically determined alteration of the
skin barrier allows penetration of environmental factors,
which are linked to a local - and systemic - immune dysreg-
ulation [2–4]. Taking into account the inflammatory nature
of the disorder and the immune-based pathogenesis of the
clinical picture (pruritus, skin hyperreactivity), topical corti-
costeroids (TCS) have always been the cornerstone of the
treatment of AD [4]. Appropriate use of TCS is character-
ized by a high efficacy, with reduced disease relapsing, and
by a low incidence of local and systemic side effects [5, 6].
Nevertheless, it is very common, in clinical practice, to
detect fear and anxiety regarding safety of TCS both among
patients affected with AD and their families and among
health care professionals [7, 8]. Such attitude towards TCS
treatment, named TCS phobia, may lead to poor adherence
to therapy and consequent treatment failure.
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With the present multicenter study, we investigated
prevalence and determinants of steroid phobia in a large
group of Italian families of pediatric patients affected by AD.
Methods
Study design
This is a multicenter, cross-sectional study conducted in the
dermatology units and general pediatric units of 9 pediatric
centers located in 9 Italian cities (Ancona, Bologna, Cesena,
Genoa, Lucca, Naples, Padova, Palermo, Rome, Bologna).
The included centers represent some of the main Italian
centers for pediatric dermatology.
From September 2013 to September 2014, families of
pediatric patients with AD consulting for the first time at
one of the above mentioned centers were consecutively en-
rolled. Inclusion criteria were age <18 years and a diagnosis
of AD. Exclusion criteria were presence of contraindications
to the use of TCS (i.e. previous sensitization to TCS, active
viral illness) and presence of other forms of dermatitis.
Prior to enrolment, one caregiver was asked to sign an
informed consent to the study.
The study was approved by the Bambino Gesù Children’s
Hospital Ethical Committee (coordinator center) and by
the Ethical Committees of all the other involved hospitals.
Questionnaire
At enrolment, a self-filling questionnaire was given to
one of the caregivers attending the patient.
The questionnaire included items on sociodemographic
characteristics, previously identified atopic conditions,
symptom duration, reason for the outpatient visit, clinical
characteristics and SCORAD index at visit, quality of life
assessment (DLQI), treatment prescriptions, previous
therapeutic education.
Finally, the questionnaire included a standardized set of
questions on fear of corticosteroids [7], divided in 3 sections.
In the first section, fear of TCS was investigated, based
on a 10-point visual analogue scale (VAS).
In the second section, specific fears and beliefs were
investigated through 21 items. The level of agreement to
each item was measured through a 4-point Lickert-scale.
In the third section, frequency of parents’ behaviours
regarding TCS treatment was investigated through 10
items based on a 4-point Lickert-scale.
Clinical parameters
AD was diagnosed according to Hanifin e Rajka criteria [9].
Severity of AD was assessed through the SCORAD index
[10]. Pruritus was evaluated daily for a week after enrolment
using the VAS score: from 0 (for no itch) to 10 (for
maximum unbearable itch).
Statistical methods
We estimated a sample size of 302, based on an expected
prevalence of TCS phobia of 80%, with a ±5% precision
level and a 97% confidence interval.
The VAS scale used for expressing fear of corticosteroids
was translated into categories as follows: 0–1: Not at all; 2–
3: A little; 4–6: Moderately; 7–8: A lot; 9–10: Very much.
The ordinal qualitative variables (based on the 4-point
Lickert scale) of the second and third section of the
questionnaire were converted into quantitative, defined
as a score ranging from 0 to 3 (0 representing a com-
pletely negative attitude towards TCS, 3 representing a
completely positive attitude).
Additionally, we classified each item of the second and
third part of the questionnaire into one category among
efficacy, safety, compliance and quality of life. We then
created 4 new “synthetic” variables, named after these cat-
egories. The value of the new variables was the sum of the
scores of the items in each category, normalized to 100.
Proportions were calculated excluding missing values.
Results of the descriptive analysis are reported as mean
and SD or median and range as appropriate.
We performed a univariate analysis through simple
linear regression to investigate factors associated with TCS
fear, among the following: sociodemographic variables
(child’s age and sex, respondent’s level of instruction);
comorbidities (celiac diseases, thyroid diseases, asthma,
allergic rhinitis, food allergy); clinical data including age at
AD diagnosis, AD duration, AD evolution, AD treatment
(emollients, systemic corticosteroids, topic TCS, systemic
immunosuppressants, topic immunosuppressants, diet),
SCORAD, median weekly pruritus, DQLI; having received
therapeutic education; each item of the second and third
section of the questionnaire and each of the synthetic vari-
ables (efficacy, safety, compliance and quality of life).
After checking for multicollinearity, multiple linear regres-
sion was used to create two multivariable models. Both
models included fear of TCS as the dependent variable, and,
as independent variables, those significantly associated with
fear of TCS (p < 0.05) at the univariate analysis. The first
model included only the single items of the questionnaire
(that were significantly associated with the outcome at the
univariate analysis). The second model included the
synthetic variables. Normality was verified with Shapiro-
Wilk test. Results were considered statistically signifi-




We consecutively enrolled a total of 300 patients with AD.
Sociodemographic characteristics are shown in Table 1.
Median age of patients was 3 years. 144/300 patients
(48%) were females.
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A large proportion of respondent caregivers had a high
education level (80% had a high school or university degree).
Twenty-seven percent of the included patients had
comorbidity, mainly asthma or allergic disorders (allergic
rhinitis or food allergy).
Regarding AD, in most cases, the disease had been diag-
nosed during the first year of life (median age at AD diagno-
sis: 5 months), and the median AD duration at enrolment
was 1.8 years. Most patients had a moderate-severe AD
(61.7%). The mean pruritus score was 5 (SD: 2).
A total of 287 patients were taking a treatment for AD at
enrolment. A large proportion of patients were on topical
steroids (82.2%), while 84% were on moisturizers. Concern-
ing other therapies, 56 patients were (19.5%) on systemic
steroids, 31 (10.8%) on topical immunosuppressants and 10
(3.5%) on systemic immunosuppressants. Almost 30% of
patients were treated with an elimination diet. Two thirds
of respondents had received therapeutic education, either
continuous or occasional.
Mean DLQI score was 3.
Descriptive and multivariate analysis
Overall, a high proportion of patients reported having
fears regarding TCS treatment: at the VAS scale, “No
fear at all” was reported by 18.8% of the enrolled pa-
tients only (A little: 26.4%, Moderately: 36.8%; A lot:
13.7%; Very much: 4.3%). Responses to the other ques-
tionnaire items are reported in (Table 2).
The multivariable analysis identified few items signifi-
cantly associated with fear of TCS treatment: believing
that TCS treatment advantages do not overweigh disad-
vantages (P = 0.011); believing that TCS may be dangerous
independently from the specific side effect (P < 0.001);
moreover, TCS fear was associated with fear of applying
too much cream (P = 0.001). Results of univariate and
multivariate analyses are reported in Additional file 1.
When subgrouping the items into categories, items con-
cerning safety were more associated with fear compared
with items concerning efficacy, compliance or quality of life.
Discussion
In the present study, we show that, in Italy, fear of TCS
is very common among families of pediatric patients af-
fected with AD.
We investigated corticophobia in an exclusively pediatric
population. Only few previous studies on TCS phobia have
been conducted on a population of children [11–14].
According to our results, fear of TCS is not motivated
by specific reasons: most respondents reported that, ac-
cording to them, TCS are dangerous independently from
the specific side effects, and the treatment disadvantages
are not balanced by its advantages. In previous studies,
the predominant concerns about TCS were cutaneous
side-effects and failure to thrive [7, 15, 16].
Old generation TCS had a high systemic absorption rate,
especially in children [17, 18]. Therefore, their long-term or
inadequate use commonly caused a variety of local and
systemic side effects, including folliculitis, erythema, re-
duced skin thickness and/or skin atrophy, striae rubrae,
Cushing-like syndrome [19]. Such side effects are still stig-
matized in the perception of the patients regarding this type
of drug, despite the excellent safety profile of new gener-
ation TCS [19, 20]. Moreover, when appropriately used,
new generation TCS are highly effective: they reduce in-
flammation, itching and relapse rate, thus dramatically im-
proving the quality of life of the patients and their families.
Our study also shows that fear of TCS is related to the
fear of applying too much cream. Thus, corticophobia
may trigger a vicious circle leading to treatment failure:
Table 1 Patients’ demographic and clinical characteristics
Females (n, %) 143 47,7
Age (median, range) 3 0.2 - 17
Comorbidity (n, %) 83 27,7





food allergy 10 3,3
other 16 5,3
Years of age at AD diagnosis (median, range) 0,4 0-13
AD duration in years (median, range) 1,8 0-15
Disease evolution (n, %)
stable 43 14,3






topical steroids 236 82,2
systemic steroids 56 19,5
topical immunosuppressants 31 10,8







Therapeutic education (n, %) 201 67
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a reduction of compliance may cause prolonged and fre-
quent relapses, which reduce trust in the treatment, thus
further decreasing compliance.
Several studies highlighted the important role of the
patient-doctor relationship in order to reduce fear of TCS
[7, 11, 14–16]. We only investigated the effect of need of
reassurance from the patient’s doctor on TCS fear, and did
not find any association. Nevertheless, as, according to
our results, corticophobia is specifically directed towards
treatment safety, it is mandatory that family pediatricians
and general physicians dedicate a consistent time of the
visit to identifying the patients’ fear of TCS, in order to ad-
dress misconceptions, thus improving the families’ trust
and compliance through evidence-based information.
Interestingly, 82% of our population was under TCS
treatment, demonstrating that, despite fear, the parents
Table 2 Response to questions on TCS specific fears and on behaviors regarding TCS use








TCS are effective over a short time period E 12 (4%) 25 (9%) 84 (30%) 155 (56%)
TCS are effective over a long time period E 81 (30%) 58 (21%) 100 (37%) 33 (12%)
TCS pass into the bloodstream S 66 (25%) 40 (15%) 92 (35%) 67 (25%)
TCS can lead to infections S 147 (56%) 55 (21%) 40 (15%) 22 (8%)
TCS make you fat S 120 (44%) 40 (15%) 69 (25%) 42 (15%)
TCS damage your skin S 59 (22%) 44 (16%) 104 (38%) 65 (24%)
TCS will affect my future health S 93 (35%) 51 (19%) 90 (33%) 35 (13%)
There is a dependency risk S 90 (33%) 35 (13%) 84 (31%) 62 (23%)
I can become resistant to TCS S 42 (16%) 44 (17%) 107 (40%) 72 (27%)
TCS become inefficient over time E 31 (12%) 39 (14%) 110 (41%) 89 (33%)
TCS calm symptoms but don’t treat the cause E 24 (9%) 25 (9%) 67 (24%) 159 (58%)
TCS make eczema worse E 152 (57%) 58 (22%) 43 (16%) 15 (6%)
TCS stop the eczema from coming up to the
surface of the skin
E 33 (12%) 37 (14%) 72 (27%) 129 (48%)
TCS can lead to asthma S 181 (72%) 36 (14%) 29 (11%) 7 (3%)
I don’t know of any side-effects but I’m still
afraid of TCS
S 43 (16%) 43 (16%) 102 (38%) 82 (30%)
TCS are more dangerous than CS in tablet form S 177 (66%) 37 (14%) 35 (13%) 18 (7%)
TCS treatment takes time and effort E 89 (32%) 74 (27%) 73 (27%) 38 (14%)
TCS treatment is complicated Q 157 (58%) 57 (21%) 38 (14%) 19 (7%)
TCS treatment helps me improve my quality of life Q 26 (9%) 27 (10%) 122 (44%) 100 (36%)
TCS increase my well-being Q 36 (13%) 31 (11%) 115 (42%) 91 (33%)
The advantages of TCS use outweigh the disadvantages Q 23 (8%) 44 (16%) 120 (44%) 87 (32%)
Behaviors regarding TCS treatment Never Sometimes Often Always
I’m afraid of applying too much cream S 76 (29%) 114 (44%) 58 (22%) 11 (4%)
I’m afraid of using the cream for too long S 49 (19%) 104 (40%) 77 (30%) 28 (11%)
I’m afraid of putting cream on certain zones like the eyelids,
where the skin is thinner
S 47 (18%) 70 (27%) 71 (27%) 73 (28%)
It’s more dangerous to use TCS on children than
on adults
S 42 (16%) 72 (28%) 75 (29%) 72 (28%)
If the doctor prescribed TCS then I would apply
the prescription
C 31 (12%) 67 (26%) 53 (20%) 109 (42%)
I wait as long as I can before applying the treatment C 72 (27%) 70 (27%) 64 (24%) 56 (21%)
I stop the treatment as soon as I can C 34 (13%) 51 (19%) 87 (33%) 90 (34%)
I am careful to rub the cream in well when I apply it S 11 (4%) 27 (10%) 71 (27%) 151 (58%)
I avoid putting TCS on my child’s hands S 78 (30%) 46 (18%) 32 (12%) 102 (40%)
I need reassurance about TCS S 44 (17%) 72 (27%) 61 (23%) 87 (33%)
E efficacy, S safety, Q quality of life, C compliance
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were compliant to the prescription of their caregivers.
Nevertheless, it is not possible to prove whether the use
of TCS was adequate.
A large proportion of participants (two thirds) had
received a therapeutic education for the management of
atopic dermatitis. However, therapeutic education did
not seem to affect fear of TCS among participants. In
Italy, a therapeutic patient education program has been
introduced in the last 5–10 years, in the third-level cen-
ters participating in the study. This education program
aims at informing the families of pediatric patients about
the disease course and at empowering them towards an
autonomous therapeutic management of the disease
[21]. The therapeutic education includes information on
the appropriate modalities for applying topical products
and on the use of distraction techniques aimed at creat-
ing a relaxing environment and at transforming the
dressing moment into a pleasant interaction between the
child and his parent [22–24]; no specific information is
actually given on the safety profile of TCS. This may
explain the lack of association between therapeutic edu-
cation and TCS fear. Therapeutic education sessions
could actually be excellent contexts for addressing TCS
fear with participating families, thus improving their
knowledge on safety and effectiveness of new generation
TCS, with a subsequent, possible reduction of TCS fear.
The present study has several limitations. The main
limitation concerns selection bias. The patients were en-
rolled from amongst those presenting to the pediatric
dermatology outpatient clinics of the above mentioned
hospitals. Nevertheless, this is a multicenter study involv-
ing hospitals that are located in different Italian regions,
therefore the sample should be sufficiently representative
of the Italian population of pediatric patients with AD.
Moreover, only a very limited number of families refused
to answer to the questionnaire, nevertheless we cannot ex-
clude that patients whose parents refused to answer to the
questionnaire differed in terms of age and sex from those
that agreed to enrolment. Another limitation concerns the
score used to assess TCS phobia. We adopted the score
proposed by Aubert-Wastiaux [7]. The same score subse-
quently informed the production of a newer scale [25],
which had good psychometric properties, but was not
available at the time of our study. The adoption of such
scale might have yielded more precise results.
Conclusion
AD is a chronic disorder and its treatment, mainly based
on topical agents, is a long-term “therapeutic manage-
ment”, rather than a common therapy. Awareness of AD
treatments’ side effects is crucial, nevertheless, truths and
misconceptions regarding this issue should be precisely
addressed in order to ensure compliance. A specific edu-
cational program should follow a holistic approach and
establish a strong relationship between the patient’s family
and caregivers. In fact, the results of our study prove the
need of implementing and focusing the therapeutic educa-
tion on the use of TCS and to spread it to all professionals
involved in the management of AD. It is mandatory that
caregivers dedicate time to inform parents about the safety
of the new generation products, whose main advantage is
a clearly improved risk/benefit ratio.
Additional file
Additional file 1: Univariate and multivariate analysis results
(dependent variable: TCS fear). (DOCX 22 kb)
Abbreviations
AD: Atopic dermatitis; DLQI: Dermatology life quality index; SCORAD: Scoring
atopic dermatitis; TCS: Topical corticosteroids; VAS: Visual analog scale
Acknowledgements
We would like to thank Mrs Lavinia Serra for her valuable logistic help and
Dr. Emanuela Carloni for her valuable contribute to the statistical analysis.
Funding
No funding.
Availability of data and materials
The datasets generated during and/or analysed during the current study are not
publicly available due to hospital research policy and lack of consent from those
interviewed. Aggregate analyses different from those presented in the article are
however available on reasonable request to the corresponding author.
Authors’ contributions
MEA, FG and AD wrote the article; IN, FA and CM conceived the study; LG,
OA, CO and SG contributed to patient enrolment and data management;
MM, and EC revised the scientific literature and designed the questionnaire;
GR, OS and ABF critically revised the article. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent to publication
Not applicable.
Ethics approval and consent to participate
The study was approved by the Bambino Gesù Children’s Hospital Ethical
Committee (protocol N. 577_OPBG_2013). An informed consent to
participation in the study was signed by parents at enrolment.
Author details
1Pediatric Dermatology Unit, Bambino Gesù Children’s Hospital, IRCCS, Rome,
Italy. 2Multifactorial Disease and Complex Phenotype Research Area, Bambino
Gesù Children’s Hospital IRCCS, Rome, Italy. 3Department of Medical and
Surgical Sciences, Pediatric Unit, S. Orsola-Malpighi Hospital - University of
Bologna, Bologna, Italy. 4Pediatric Dermatology, AORN Santobono-Pausilipon,
Naples, Italy. 5Dermatology Unit, Istituto Giannina Gaslini, Genoa, Italy.
6Department of Medicine, Pediatric Dermatology Unit, University of Padua,
Padua, Italy. 7Department of Medicine, Unit of Pediatric Dermatology, ARNAS
Civico, Palermo, Italy. 8Dermatology Unit, M. Bufalini Hospital, Cesena, Italy.
9Department of Clinical and Molecular Sciences, Clinic of Dermatology,
Università Politecnica delle Marche, Ancona, Italy. 10Dermatology Unit, San
Luca Hospital, ASL 2, Lucca, Italy. 11Division of Dermatology, Department of
Specialised, Experimental and Diagnostic Medicine, University of Bologna, S.
Orsola-Malpighi Hospital, Bologna, Italy.
Received: 9 August 2016 Accepted: 14 January 2017
El Hachem et al. Italian Journal of Pediatrics  (2017) 43:22 Page 5 of 6
References
1. Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A.
Investigating international time trends in the incidence and prevalence of
atopic eczema 1990–2010: a systematic review of epidemiological studies.
PLoS One. 2012;7:7.
2. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin
barrier and immune dysregulation. Immunol Rev. 2011;242:1.
3. Leung DY. New insights into atopic dermatitis: role of skin barrier and
immune dysregulation. Allergol Int. 2013;62:2.
4. Wolter S, Price HN. Atopic dermatitis. Pediatr Clin North Am. 2014;61:2.
5. Charman C, Williams H. The use of corticosteroids and corticosteroid phobia
in atopic dermatitis. Clin Dermatol. 2003;21:3.
6. Furue M, Terao H, Rikihisa W, Urabe K, Kinukawa N, Nose Y, et al. Clinical
dose and adverse effects of topical steroids in daily management of atopic
dermatitis. Br J Dermatol. 2003;148:1.
7. Aubert-Wastiaux H, Moret L, Le Rhun A, Fontenoy AM, Nguyen JM, Leux C,
et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature,
origins and frequency. Br J Dermatol. 2011;165:4.
8. Kojima R, Fujiwara T, Matsuda A, Narita M, Matsubara O, Nonoyama S, et al.
Factors associated with steroid phobia in caregivers of children with atopic
dermatitis. Pediatr Dermatol. 2013;30:1.
9. Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm
Venereol (Stockh). 1980;92:44–47.
10. Severity scoring of atopic dermatitis: The SCORAD index. consensus report of
the european task force on atopic dermatitis. Dermatology. 1993;186(1):23–31.
11. Fischer G. Compliance problems in paediatric atopic eczema. Australas J
Dermatol. 1996;37 Suppl 1:S10–3.
12. Ohya Y, Williams H, Steptoe A, Saito H, Iikura Y, Anderson R, et al.
Psychosocial factors and adherence to treatment advice in childhood atopic
dermatitis. J Invest Dermatol. 2001;117:4.
13. Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the
treatment of childhood atopic dermatitis. Clin Exp Dermatol. 2003;28:5.
14. Smith SD, Hong E, Fearns S, Blaszczynski A, Fischer G. Corticosteroid phobia
and other confounders in the treatment of childhood atopic dermatitis
explored using parent focus groups. Australas J Dermatol. 2010;51:3.
15. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in
patients with atopic eczema. Br J Dermatol. 2000;142:5.
16. Hon KL, Kam WY, Leung TF, Lam MC, Wong KY, Lee KC, et al. Steroid fears
in children with eczema. Acta Paediatr. 2006;95:11.
17. West DP, Worobec S, Solomon LM. Pharmacology and toxicology of infant
skin. J Invest Dermatol. 1981;76:3.
18. Turpeinen M. Influence of age and severity of dermatitis on the percutaneous
absorption of hydrocortisone in children. Br J Dermatol. 1988;118:4.
19. Brazzini B, Pimpinelli N. New and established topical corticosteroids in
dermatology: clinical pharmacology and therapeutic use. Am J Clin
Dermatol. 2002;3:1.
20. Callen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M, Goldfarb M, et al. A
systematic review of the safety of topical therapies for atopic dermatitis. Br J
Dermatol. 2007;156:2.
21. Ricci G, Bendandi B, Aiazzi R, Patrizi A, Masi M. Three years of italian experience
of an educational program for parents of young children affected by atopic
dermatitis: Improving knowledge produces lower anxiety levels in parents of
children with atopic dermatitis. Pediatr Dermatol. 2009;26:1.
22. Chavigny JM. The role of therapeutic education in the treatment of atopic
dermatitis in children. Ann Dermatol Venereol. 2005;132 Spec No 1:1S116-20.
23. Barbarot S, Bernier C, Deleuran M, De Raeve L, Eichenfield L, El Hachem M, et al.
Therapeutic patient education in children with atopic dermatitis: position paper
on objectives and recommendations. Pediatr Dermatol. 2013;30:2.
24. Ersser SJ, Cowdell F, Latter S, Gardiner E, Flohr C, Thompson AR, et al.
Psychological and educational interventions for atopic eczema in children.
Cochrane Database Syst Rev. 2014;1:CD004054.
25. Moret L, Anthoine E, Aubert-Wastiaux H, Le Rhun A, Leux C, Mazereeuw-
Hautier J, et al. TOPICOP©: a new scale evaluating topical corticosteroid
phobia among atopic dermatitis outpatients and their parents. PLoS One.
2013;8:e76493.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
El Hachem et al. Italian Journal of Pediatrics  (2017) 43:22 Page 6 of 6
